Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 901–1,000 of 1,005
In utero therapy for spinal muscular atrophy: closer to clinical translation
Tizzano, E. F., Lindner, G., Chilcott, E. M., Finkel, R. S., & Yáñez‐Muñoz, R. J. (2025) · Brain · doi:10.1093/brain/awaf123 · Cited by 20
“64,65 There are currently only limited data on the treatment of premature babies.”
Belter, L. T., Jarecki, J., Reyna, S. P., Cruz, R. E., Jones, C. C., Schroth, M. K., O'Toole, C., O’Brien, S., Hall, S. A., Johnson, N. B., et al. (2020) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200563 · Cited by 19
“Subsequent SMA surveys are likely to reveal the impact of newborn screening and early treatment on survival and motor function on infantile-onset SMA, as shown in clinical trials and retrospective studies [22, 26, 52, 53].”
BackgroundPietersz, K. L., Plessis, F. D., Pouw, S. M., Liefhebber, J. M. P., van Deventer, S. J. H., Martens, G. J. M., Konstantinova, P. S., & Blits, B. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.679483 · Cited by 21
Schwab, M. E., & MacKenzie, T. C. (2021) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000655 · Cited by 23
Gene Therapy Cargoes Based on Viral Vector Delivery
Lundstrom, K. H. (2022) · Current Gene Therapy · doi:10.2174/1566523222666220921112753 · Cited by 20
Significant healthcare burden and life cost of spinal muscular atrophy: real-world data
Chan, H. S., Wong, C. K. H., Wu, T., Wong, W. H. S., Yu, M. K. L., Au, I. C. H., & Chan, G. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01548-5 · Cited by 25
“In separate studies, following onasemnogene abeparvovec-xioi [17], risdiplam [18] and nusinersen [28] treatment, better clinical outcomes, such as higher motor gain and event-free survival, were seen in SMA1 infants who were treated at an earlier symptomatic stage before 3 months of age.”
ResultAre we prepared to deliver gene‐targeted therapies for rare diseases?
Yu, T. W., Kingsmore, S. F., Green, R. C., MacKenzie, T. C., Wasserstein, M., Caggana, M., Gold, N. B., Kennedy, A., Kishnani, P. S., Might, M., et al. (2023) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32029 · Cited by 19
“that can be used to treat SMA with a single dose of intravenous adeno-associated virus carrying the intact, corrected SMN1 gene (Mendell et al., 2017).”
BackgroundComputer-Aided Directed Evolution Generates Novel AAV Variants with High Transduction Efficiency
Han, Z., Luo, N., Wang, F., Cai, Y., Yang, X., Feng, W., Zhu, Z., Wang, J., Wu, Y., Ye, C., et al. (2023) · Viruses · doi:10.3390/v15040848 · Cited by 23
“Adeno-associated viruses (AAVs) have become safe and effective tools for the in vivo delivery of therapeutic gene drugs due to their relatively low immune responses and broad tissue tropism [1,2].”
BackgroundSoini, V., Schreiber, G., Wilken, B., & Hell, A. K. (2023) · Children · doi:10.3390/children10060998 · Cited by 25
Recent advances in the management and implementation of care for familial hypercholesterolaemia
Lan, N. S. R., Bajaj, A., Watts, G. F., & Cuchel, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106857 · Cited by 22
Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases
Li, L., Vasan, L., Kartono, B., Clifford, K. P., Attarpour, A., Sharma, R., Mandrozos, M., Kim, A., Zhao, W., Belotserkovsky, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102725 · Cited by 20
“Despite these promising initial results, follow-up studies indicated that rAAV9 vector administration may cause elevated levels of detoxifying liver transaminases [24], possibly reflecting compromised liver function.”
Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability
Armengol, V. D., Darras, B. T., Abulaban, A. A., Alshehri, A. M., Barišić, N., Ben‐Omran, T., Bernert, G., Castiglioni, C., Chien, Y., Farrar, M. A., et al. (2023) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200224 · Cited by 24
Using focused ultrasound to modulate microglial structure and function
Grewal, S., de Andrade, E. G., Kofoed, R. H., Matthews, P. M., Aubert, I., Tremblay, M., & Morse, S. V. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1290628 · Cited by 23
Notarte, K. I., Catahay, J. A., Macasaet, R., Liu, J., Velasco, J. V., Peligro, P. J., Vallo, J., Goldrich, N., Lahoti, L., Zhou, J., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29305 · Cited by 21
“17,19,27,62 It is essential to have steroid drug vials readily available at infusion sites during monitoring, considering the potential for delayed onset IARs.”
BackgroundTreatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy
MUÑOZ, S. A., Bertolin, J., Jiménez, V., Jaén, M. L., García, M., Pujol, A., Vilà, L., Sacristan, V., Barbon, E., Ronzitti, G., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101899 · Cited by 22
Bitetti, I., Manna, M. R., Stella, R., & Varone, A. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1326528 · Cited by 24
Borges, B., Varthaliti, A., Schwab, M. E., Clarke, M. T., Pivetti, C. D., Gupta, N. M., Cadwell, C. R., Guibinga, G.-H., Phillips, S., del Rio, T., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101263 · Cited by 21
“19 Another AAV9 vector was recently approved for i.v. delivery in children with Duchenne muscular dystrophy (DMD) aged 4 – 8 years, 20 and AAV vectors are also being studied for intrathecal delivery to treat giant axonal neuropathy (NCT02362438).”
Spinal Muscular Atrophy Scoliosis in the Era of Background Therapies—A Review of the Literature
Ruythooren, F., & Moens, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123467 · Cited by 21
“Once it is inside the central nervous system (CNS), the vector is endocytosed by cells, including motor neurons, where it transduces host cells to transcribe its double-stranded DNA [32,35,36].”
BackgroundInfluentialProprioceptive synaptic dysfunction is a key feature in mice and humans with spinal muscular atrophy
Simon, C. M., Delestrée, N., Montes, J., Sowoidnich, L., Gerstner, F., Carranza, E., Buettner, J. M., Pagiazitis, J. G., Prat-Ortega, G., Ensel, S., et al. (2025) · Brain · doi:10.1093/brain/awaf074 · Cited by 22
Crowgey, E. L., Washburn, M. C., Kolb, E. A., & Puffenberger, E. G. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.03.004 · Cited by 20
Belur, L. R., Podetz-Pedersen, K. M., Tran, T., Mesick, J. A., Singh, N. M., Riedl, M., Vulchanova, L., Kozarsky, K., & McIvor, R. (2020) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2020.100604 · Cited by 22
Gene Therapy for Monogenic Inherited Disorders: Opportunities and Challenges
Kirschner, J., & Cathomen, T. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0878 · Cited by 33
“24 months after the treatment, all treated children were event-free—that is, they survived without long-term ventilation—compared with less than 8% over the natural course (11).”
BackgroundShort-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy
Lee, S., Lee, Y. J., Kong, J., Ryu, H. W., Shim, Y., Han, J. Y., Woo, H., Kim, S. Y., Cho, A., Lim, B. C., et al. (2022) · Brain and Development · doi:10.1016/j.braindev.2021.12.006 · Cited by 20
The Dilemma of Two Innovative Therapies for Spinal Muscular Atrophy
van der Ploeg, A. T. (2017) · New England Journal of Medicine · doi:10.1056/nejme1712106 · Cited by 19
Clinical recommendations: The role of mechanisms in the GRADE framework
Perillat, L., & Mercuri, M. (2022) · Studies in History and Philosophy of Science Part A · doi:10.1016/j.shpsa.2022.08.018 · Cited by 19
Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials
Tiwade, P. B., Fung, V., VanKeulen‐Miller, R., Narasipura, E. A., Ma, Y., & Fenton, O. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00871 · Cited by 21
Neutralizing Antibodies: Role in Immune Response and Viral Vector Based Gene Therapy
Tsaregorodtseva, T. S., Gubaidullina, A. A., Kayumova, B. R., Shaimardanova, A. A., Issa, S. S., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115224 · Cited by 20
“However, studies have shown that the therapy does not yield the expected effect in some patients, while others exhibit rapid and significant improvement [3].”
Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors
Tulalamba, W., Weinmann, J., Pham, Q. H., Andari, J. E., VandenDriessche, T., Chuah, M., & Grimm, D. (2019) · Gene Therapy · doi:10.1038/s41434-019-0106-3 · Cited by 18
Banning, A., Zakrzewicz, A., Chen, X., Gray, S. J., & Tikkanen, R. (2021) · Cells · doi:10.3390/cells10051259 · Cited by 19
“In addition, intravenous gene therapy with an AAV9 vector, Onasemnogene abeparvovec, is currently also tested in clinical trials for various forms of spinal muscular atrophy (SMA) [16].”
BackgroundA high-throughput genome-wide RNAi screen identifies modifiers of survival motor neuron protein
McCormack, N. M., Abera, M. B., Arnold, E. S., Gibbs, R. M., Martin, S. E., Buehler, E. C., Chen, Y., Chen, L., Fischbeck, K. H., & Burnett, B. G. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109125 · Cited by 19
“Although some patients have significant improvements in their ability to sit, walk, and run, other patients see little to no improvement in their motor function (Aragon-Gawinska et al., 2020; Finkel et al., 2017; Mendell et al., 2017; Mercuri et al., 2018).”
BackgroundMethodMotor Neuron Diseases and Neuroprotective Peptides: A Closer Look to Neurons
Zuccaro, E., Piol, D., Basso, M., & Pennuto, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.723871 · Cited by 19
“PACAP was first identified in Miyata et al. (1989) as a regulatory peptide that increases AC activity in the anterior pituitary cells, observation from which they coined its name.”
BackgroundRespiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen
Menard, J., Seferian, A., Fleurence, E., Barzic, A., Binoche, A., Labouret, G., Coutier, L., Vuillerot, C., Bieleu, B. M., de la Banda, M. G. G., et al. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.25899 · Cited by 21
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients
Berti, B., Fanelli, L., Stanca, G., Onesimo, R., Palermo, C., Leone, D., Sanctis, R. D., Carnicella, S., Norcia, G., Forcina, N., et al. (2022) · Archives of Disease in Childhood · doi:10.1136/archdischild-2022-323899 · Cited by 19
Chandran, J. S., Chowdhury, E. A., Perkinton, M. S., Jamier, T., Sutton, D., Wu, S., Dobson, C., Shah, D. K., Chessell, I. P., & Meno‐Tetang, G. M. L. (2022) · Gene Therapy · doi:10.1038/s41434-022-00346-1 · Cited by 20
“The use of AAVs in the treatment of CNS disorders in clinical trials [5, 23] has highlighted their potential for delivering therapeutic transgenes to cell populations that have been historically difficult to target with small molecules.”
BackgroundAmyotrophic lateral sclerosis mimics
Kwan, J. Y., & Vullaganti, M. (2022) · Muscle & Nerve · doi:10.1002/mus.27567 · Cited by 28
“accurately make this diagnosis although it is uncertain whether patients with adult-onset forms will derive similar benefits from therapy.(127,128) Rarely, SMA is caused by a mutation in a gene other than”
BackgroundProgress in spinal muscular atrophy research
Wurster, C. D., & Petri, S. (2022) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001102 · Cited by 18
“After promising preclinical trials [53] a phase 1 open-label dose escalation trial (START) showed impressive improvements in survival and motor milestones in all treated infants [54].”
BackgroundSLC13A5 Deficiency Disorder: From Genetics to Gene Therapy
Goodspeed, K., Liu, J. S.-H., Nye, K., Prasad, S., Sadhu, C., Tavakkoli, F., Bilder, D. A., Minassian, B. A., & Bailey, R. M. (2022) · Genes · doi:10.3390/genes13091655 · Cited by 20
“Among the different serotypes of AAVs, AAV9 can cross the blood–brain barrier relatively more efficiently, transduce neurons and glial cells, and has previously been used as a vector for gene therapy for SMA [30,31] and other rare neurological disorders, such as GAN (NCT02362438) [33].”
BackgroundAssessing Bulbar Function in Spinal Muscular Atrophy Using Patient-Reported Outcomes
Young, S. D., Pasternak, A. E., Duong, T., McGrattan, K. E., Stranberg, S., Maczek, E., Dias, C., Tang, W. J., Parker, D. M., Levine, A., et al. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221573 · Cited by 20
An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy
Li, Y., Zeng, H., Wei, Y., Ma, X., & He, Z. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.189 · Cited by 20
“Mendell et al. 75 conducted the first phase of a clinical trial (START) funded by AveXis and others, where 15 patients with SMA1 received a single IV dose of onasemnogene abeparvovec.”
Chen, T., Chang, S.-H., Wu, Y.-F., Yen, Y.-P., Hsu, F., Chen, Y., Yang, M., Hsu, H.-C., Su, Y., Wong, S.-T., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.03.005 · Cited by 20
Shell, R. D., McGrattan, K. E., Hurst-Davis, R., Young, S. D., Baranello, G., Lavrov, A., O’Brien, E. J., Wallach, S., LaMarca, N. M., Reyna, S. P., et al. (2023) · Neuromuscular Disorders · doi:10.1016/j.nmd.2023.06.005 · Cited by 18
“Clinical trials demonstrated improved survival and motor function, as well as achievement of milestones such as sitting without support, standing alone, and walking alone, after administration of onasemnogene abeparvovec for infants with SMA type 1 [26–28] .”
BackgroundMethodSelf-citationDeng, C., & Chen, H. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106377 · Cited by 18
“Spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) are the most common forms of fatal motor neuron diseases, characterized by the degeneration of motor neurons (MNs) and muscle atrophy (Mendell et al., 2017; Taylor et al., 2016).”
Viral Vectors in Gene Replacement Therapy
Minskaia, E., Galieva, A., Egorov, A. D., Ivanov, R. A., & Karabelsky, A. V. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923120179 · Cited by 24
Zanoteli, E., Araújo, A. P. D. Q. C., Becker, M. M., Fortes, C. P. D. D., França, M. C., Costa, M. C. M., Marques, W., Matsui, C., Mendonça, R. D. H., Nardes, F., et al. (2024) · Arquivos de Neuro-Psiquiatria · doi:10.1055/s-0044-1779503 · Cited by 30
“90 This gene replacement therapy aims to provide continuous expression of SMN protein in the body, effectively addressing the underlying cause of SMA-5q.”
BackgroundMethodInfluentialThrombotic Microangiopathy as an Emerging Complication of Viral Vector–Based Gene Therapy
Schwotzer, N., Sissy, C. E., Desguerre, I., Frémeaux‐Bacchi, V., Servais, L., & Fakhouri, F. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.04.024 · Cited by 22
“In contrast, in vivo , complement activation occurs 25% – 90% of patients may have subclinical elevation of liver enzymes within 7 days of after i.v. infusion of high-dose viral vectors 30,31 (toxicity delayed up to 4 – 10 wk for low-dose viral vectors infusion), with a 2nd peak at 1 mo.”
BackgroundZaidman, C. M., Crockett, C. D., Wedge, E., Tabatabai, G. M., & Goedeker, N. L. (2024) · International Journal of Neonatal Screening · doi:10.3390/ijns10030058 · Cited by 24
“Three SMN protein-directed therapeutics are currently U.S. Food and Drug Administration (FDA)-approved for treatment of SMA based on improved outcomes in children with SMA [1–4].”
Pushing the boundaries: future directions in the management of spinal muscular atrophy
Moultrie, F., Chiverton, L., Butler, I., Lilien, C., & Servais, L. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.12.006 · Cited by 20
Pearson, S. D., Thokala, P., Stevenson, M., & Rind, D. M. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.12.1300 · Cited by 24
“We chose to present this model at the time due to our understanding that data on Zolgensma for presymptomatic SMA would be forthcoming, and we felt it important to provide a context for policymakers to consider the potential cost-effectiveness of a one-time treatment for presymptomatic SMA.”
MethodInfluentialSponsorship and Funding for Gene Therapy Trials in the United States
Kassir, Z. M., Sarpatwari, A., Kocak, B. R., Kuza, C. C., & Gellad, W. F. (2020) · JAMA · doi:10.1001/jama.2019.22214 · Cited by 18
Generating ventral spinal organoids from human induced pluripotent stem cells
Hor, J., & Ng, S. (2020) · Methods in cell biology · doi:10.1016/bs.mcb.2020.03.010 · Cited by 21
Gene Therapy for Rare Neurological Disorders
Flotte, T. R., & Gessler, D. J. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2543 · Cited by 23
“Notably, 4/12 (33%) patients in the high- dose group displayed treatment- associated adverse effects, such as elevated liver enzymes.(91) Further evaluation of safety and efficacy in a phase III clinical trial (STR1VEUS (Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1)) rev…”
BackgroundSurvival motor neuron protein deficiency alters microglia reactivity
Khayrullina, G., Alipio‐Gloria, Z. A., Deguise, M., Gagnon, S., Chehadé, L., Stinson, M. W., Belous, N., Bergman, E. M., Lischka, F. W., Rotty, J. D., et al. (2022) · Glia · doi:10.1002/glia.24177 · Cited by 20
“Current FDA approved therapeutics, Risdiplam (Evrysdi™), Nusinersen (Spinraza®), and Onasemnogene ebeparvovec (Zolgensma®) aim to increase levels of SMN protein (Groen, 2018; Mendell et al., 2017; Mercuri et al., 2018; Messina & Sframeli, 2020).”
BackgroundD’Silva, A., Kariyawasam, D. S. T., Venkat, P., Mayoh, C., & Farrar, M. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010170 · Cited by 19
“of SMN2 pre-mRNA to promote expression of functional SMN protein [6,7].”
BackgroundMerjane, J., Chung, R. S., Patani, R., & Lisowski, L. (2023) · Medicinal Research Reviews · doi:10.1002/med.21937 · Cited by 20
“126 One of the biggest current limitations in the field of gene therapy is the development of vehicles which can transport the therapeutic cassette to the cell type of interest in a safe, efficient and specific manner.”
Clinical trial design for Friedreich ataxia - Where are we now and what do we need?
Rummey, C., Kichula, E. A., & Lynch, D. R. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1449638 · Cited by 17
Canestrari, E., & Paroo, Z. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.07.005 · Cited by 20
The Role of Gene Therapy in Cartilage Repair.
Rodriguez-Merchan, E. C., & Valentino, L. A. (2019) · Europe PMC (PubMed Central) · doi:10.22038/abjs.2018.31615.1827 · Cited by 23
Can laboratory model systems instruct human limb regeneration?
Cox, B. D., Yun, M. H., & Poss, K. D. (2019) · Development · doi:10.1242/dev.181016 · Cited by 18
Combinatorial treatment for spinal muscular atrophy
Poletti, A., & Fischbeck, K. H. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.14974 · Cited by 18
“Restoration of normal SMN1 levels in affected cells has been achieved using adeno-associated virus serotype 9 (AAV9) vector to deliver the cDNA encoding SMN1 (onasemnogene abeparvovecxioi, Zolgensma®) (Mendell et al. 2017).”
MethodInfluentialMachine-guided design of synthetic cell type-specific cis -regulatory elementsPreprint
Gosai, S. J., Castro, R. I., Fuentes, N., Butts, J. C., Kales, S., Noche, R. R., Mouri, K., Sabeti, P. C., Reilly, S. K., & Tewhey, R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.08.552077 · Cited by 18
Lüscher, C., Emiliani, V., Farahany, N. A., Gittis, A. H., Gradinaru, V., High, K. A., Roska, B., Sahel, J., Yizhar, O., Zeng, H., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02097-9 · Cited by 30
“…for a rare form of inherited blindness) 171 and, for diseases that only involve the pediatric population, (2) estimating a safe and potentially therapeutic dose based on animal studies and beginning with that dose (for example, onasemnogene abeparvovec (Zolgensma) for spinal muscular atrophy) 172 .”
Muscle cell differentiation and development pathway defects in Emery-Dreifuss muscular dystrophy
Storey, E. C., Holt, I., Morris, G. E., & Fuller, H. R. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.04.002 · Cited by 17
Burr, P., & Reddivari, A. K. R. (2021) · StatPearls · Cited by 17
Cao, Y., Cheng, M., Qu, Y.-J., Bai, J.-L., Peng, X., Ge, X., Jin, Y., Wang, H., & Song, F. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.03.002 · Cited by 20
Systematic Literature Review of Clinical and Economic Evidence for Spinal Muscular Atrophy
Yang, M., Awano, H., Tanaka, S., Toro, W., Zhang, S., Dabbous, O. H., & Igarashi, A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02089-2 · Cited by 21
“STR1VE-US (NCT03306277) [13], a completed Phase III study, demonstrated that the favorable riskbenefit profile first observed in START [12] was confirmed for a larger group of patients (n = 22 vs. n = 15).”
BackgroundResultInfluentialDetering, N. T., Schüning, T., Hensel, N., & Claus, P. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04522-9 · Cited by 20
Latzer, I. T., Sagi, L., Lavi, R., Aharoni, S., Bistritzer, J., Noyman, I., Ginsburg, M., Lev-Or, A., Katzenellenbogen, S., Nevo, Y., et al. (2023) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2023.04.007 · Cited by 19
MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy
Giraud, Q., Spiegelhalter, C., Messaddeq, N., & Laporte, J. (2023) · Brain · doi:10.1093/brain/awad251 · Cited by 19
“37 Concerning CNM, there is no clinical trial planned yet for BIN1 -CNM.”
Pediatric Neuromuscular Diseases
Rathore, G., & Kang, P. B. (2023) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2023.08.034 · Cited by 21
Insight Into the Degradation Pathways of an AAV9
Rodriguez, A., Jalimarada, S. S., Banazadeh, A., Afroz, S., Ali, A., Deng, K., Huang, L., Galibert, L., Singh, R., & Zhou, C. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.05.034 · Cited by 16
Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super Babies for SMA!
Bartlett, A., Kolb, S. J., Kingsley, A., Swoboda, K. J., Reyna, S. P., Sakonju, A., Darras, B. T., SHELL, R. D., Kuntz, N. L., Castro, D., et al. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.07.002 · Cited by 17
Self-citationA Matter of Genes: The Hurdles of Gene Therapy for Epilepsy
Ingusci, S., Cattaneo, S., Verlengia, G., Zucchini, S., & Simonato, M. (2019) · Epilepsy Currents · doi:10.1177/1535759718822846 · Cited by 15
Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies
Adami, R., & Bottai, D. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09910-6 · Cited by 19
“(scAAV9) that mediates SMN1 gene replacement by a single dose treatment and also was found to be effective in the very early stages of the pathology [43].”
BackgroundSpinal muscular atrophy — new therapies, new challenges
Jędrzejowska, M., & Kostera‐Pruszczyk, A. (2020) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2019.0068 · Cited by 17
Gene and Cell Therapy for Cardiac Arrhythmias
Ravindran, D., Kok, C., Farraha, M., Selvakumar, D., Clayton, Z. E., Kumar, S., Chong, J. J. H., & Kizana, E. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.09.001 · Cited by 17
Spinal Cord Injury — Healing from Within
Monje, M. (2021) · New England Journal of Medicine · doi:10.1056/nejmcibr2030836 · Cited by 17
Axford, J., Sung, M. J., Manchester, J. I., Chin, D. N., Jain, M., Shin, Y., Dix, I., Hamann, L. G., Cheung, A. K., Sivasankaran, R., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02173 · Cited by 18
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)
Paracha, N., Hudson, P., Mitchell, S., & Sutherland, C. S. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01095-6 · Cited by 20
Yonekawa, T., Rauckhorst, A. J., El-Hattab, S., Cuellar, M. A., Venzke, D. P., Anderson, M. E., Okuma, H., Pewa, A. D., Taylor, E. B., & Campbell, K. P. (2022) · Science Advances · doi:10.1126/sciadv.abn0379 · Cited by 16
New Therapeutics Options for Pediatric Neuromuscular Disorders
Flotats‐Bastardas, M., & Hahn, A. (2020) · Frontiers in Pediatrics · doi:10.3389/fped.2020.583877 · Cited by 18
“An indirect unanchored comparison of the two pivotal trials (7, 12) among symptomatic SMA type 1 infants suggested that onasemnogene abeparvovec may have an efficacy advantage relative to nusinersen (25), but this study has been criticized because of substantial methodological shortcomings (26).”
Adeno-associated virus (AAV) reduces cortical dendritic complexity in a TLR9-dependent mannerPreprint
Suriano, C. M., Verpeut, J. L., Kumar, N., Ma, J., Jung, C., & Boulanger, L. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.28.462148 · Cited by 17
Tkaczyk, C., Newton, M. R., Patnaik, M. M., Thom, G., Strain, M., Gamson, A., Daramola, O., Murthy, A., Douthwaite, J. A., Stepanov, O., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.036 · Cited by 19
Maurizi, N., Ammirati, E., Silver, E., Hong, K., Bui, Q. M., Argirò, A., Olivotto, I., & Adler, E. D. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.004 · Cited by 20
Pediatric neuromuscular disorders: Care considerations during the COVID-19 pandemic
Stratton, A., Roberts, R. O., III, Kupfer, O., Carry, T., Parsons, J. A., & Apkon, S. D. (2020) · Journal of Pediatric Rehabilitation Medicine · doi:10.3233/prm-200768 · Cited by 18
“For those living with neuromuscular conditions, the treatment landscape is changing with many novel therapies in clinical trial and some receiving FDA approval [37,38].”
BackgroundSoukupovà, M., Zucchini, S., Trempat, P., Ingusci, S., Biollay, C., Barbieri, M., Cattaneo, S., Bettegazzi, B., Falzoni, S., Berthommé, H., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.03.020 · Cited by 16
Sheikh, O., & Yokota, T. (2021) · BioDrugs · doi:10.1007/s40259-021-00486-7 · Cited by 21
Macdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 18
“104 Even more recently, as already mentioned earlier, a phase II AAV gene therapy clinical trial for X-linked myotubular myopathy had to be suspended after three deaths due to progressive liver toxicity in response to the high AAV vector doses.”
Genetic therapies for neurological disorders
FitzPatrick, L., & Bird, A. P. (2021) · Human Genetics · doi:10.1007/s00439-021-02399-5 · Cited by 21
Gavriilaki, M., Papaliagkas, V. T., Stamperna, A., Moschou, M., Notas, K., Papagiannopoulos, S., Arnaoutoglou, M., & Kimiskidis, V. Κ. (2022) · Acta Neurologica Belgica · doi:10.1007/s13760-022-02028-6 · Cited by 16
Adeno-associated virus vector-based gene therapies for pediatric diseases
Muramatsu, K., & Muramatsu, S. (2022) · Pediatrics & Neonatology · doi:10.1016/j.pedneo.2022.09.004 · Cited by 16
“Intravenous administration of an AAV9 vector expressing the SMN1 gene has demonstrated remarkable efficacy, including promoting independent walking.(15) Antisense oligonucleotides that increase the expression of functional SMN protein by targeting the mRNA of the SMN2 gene, which differs by five nucleotides from SMN1,…”
BackgroundAdvances of Multiplex Ligation-dependent Probe Amplification Technology in Molecular Diagnostics
Fu, X., Shi, Y., Ma, J.-Y., Zhang, K., Wang, G., Li, G., Lei, X., & Wang, H. (2022) · BioTechniques · doi:10.2144/btn-2022-0017 · Cited by 16
Duchenne Muscular Dystrophy Gene Therapy
Saad, F. A., Saad, J. F., Siciliano, G., Merlini, L., & Angelini, C. I. (2022) · Current Gene Therapy · doi:10.2174/1566523223666221118160932 · Cited by 19
Yang, T., Chen, Y., Xu, Y., Liu, X., Yang, M., & Mao, C. (2023) · Materials Science and Engineering R Reports · doi:10.1016/j.mser.2023.100715 · Cited by 18
Hughes, M., Nelvagal, H., Coombe-Tennant, O., Smith, D., Smith, C., Massaro, G., Poupon-Bejuit, L., Platt, F., & Rahim, A. (2023) · Cells · doi:10.3390/cells12121619 · Cited by 16
“Following the recent regulatory approval and licensing of the adeno-associated viral vector (AAV)-based gene therapy Zolgensma for the treatment of spinal muscular atrophy [14,15], there is hope for this approach in other neurological diseases including NP-C.”
BackgroundInfluentialUbiquitin-protein ligase E3A (UBE3A) mediation of viral infection and human diseases
Chaudhary, P., Proulx, J. M., & Park, I.-W. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199191 · Cited by 17
“disorders have been approved by Food and Drug Administration (FDA) (Mendell et al., 2017; Moore et al., 2018).”
BackgroundChiang, J., Xiao, L., Nigro, E., St‐Laurent, A., Weinstock, L., Law, E., Janevski, J., Kuyntjes, S., Cithiravel, N., Tran, T., et al. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.09.019 · Cited by 15
Lim, D. Y., & Hwang, B. H. (2023) · Biotechnology Journal · doi:10.1002/biot.202300156 · Cited by 17
Lu, M., Lee, Z., & Hu, W. (2024) · Biotechnology Progress · doi:10.1002/btpr.3428 · Cited by 18
Advances in Pompe Disease Treatment: From Enzyme Replacement to Gene Therapy
Colella, P. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00733-x · Cited by 24
“However, both assays lack standardization across centers, leading to variable exclusion thresholds [147, 154].”
Gene therapy for the leukodystrophies: From preclinical animal studies to clinical trials.
Metovic, J., Li, Y., Gong, Y., & Eichler, F. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00443 · Cited by 16
“Many IV AAV-mediated gene therapies in clinical trials are in this high dose range [224 – 226].”
Background
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.